BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:
Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma.
This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).